ライフサイエンスコーパス: oxyntomodulin

1 eceptor activation of the endogenous peptide oxyntomodulin.

2 characterized to induce biased signaling by oxyntomodulin.

3 3-36) or oxyntomodulin or combined PYY(3-36)/oxyntomodulin.

4 nously via minipumps with either saline, rat oxyntomodulin (0.47 nmol x kg(-1) x h[-1]), or glucagon

5 The hypothesis that infusions of oxyntomodulin, a bioactive form of enteroglucagon, would

6 -36) (PYY(3-36)), a Y2 receptor agonist, and oxyntomodulin, a glucagon-like peptide 1 (GLP-1) recepto

7 We show that oxyntomodulin, a peptide with potential to treat obesity

8 Met-303 was more important for exendin-4 and oxyntomodulin action than those of GLP-1 peptides.

9 ion binding studies were used to investigate oxyntomodulin activity on the GLP-1 receptor in the pres

10 In contrast, oxyntomodulin and glucagon significantly stimulated tota

11 on other gut hormones such as GIP, ghrelin, oxyntomodulin and peptide YY.

12 Oxyntomodulin and the growth hormone-(1-43) fragment wer

13 cholecystokinin, glucagon-like peptide 1 and oxyntomodulin) and orexigenic (ghrelin and orexin A) pep

14 endogenous ligands glucagon-like peptide-1, oxyntomodulin, and the clinically used mimetic exendin-4

15 aling of the peptide mimetics, exendin-4 and oxyntomodulin, as well as small molecule allosteric agon

16 BETP increased oxyntomodulin binding affinity for the GLP-1 receptor an

17 greatly prolonged exposure, with a constant oxyntomodulin bioactivity detectable in serum for at lea

18 The anorectic effects of PYY(3-36) and oxyntomodulin can be additive in overweight and obese hu

19 ether the anorectic effects of PYY(3-36) and oxyntomodulin can be additive.

20 granin A (CgA), serotonin, peptide YY (PYY), oxyntomodulin (enteroglucagon), pancreatic polypeptide,

21 r peptide agonists; glucagon-like peptide-1, oxyntomodulin, exendin-4 and exendin-P5.

22 ation of glicentin as well as low amounts of oxyntomodulin, GLP-1, truncated GLP-1, and N-terminally

23 Oxyntomodulin has been shown to reduce weight and food i

24 ecause of the unique metabolic properties of oxyntomodulin, identifying molecules that enhance its ac

25 e results support a new, specific action for oxyntomodulin in intestinal adaptation as a glucose upta

26 avenous glucose tolerance test characterized oxyntomodulin-induced insulin secretion in animals admin

27 In addition, oxyntomodulin-induced insulin secretion was enhanced in

28 important for GLP-1- and exendin-4-, but not oxyntomodulin-mediated cAMP formation and also ERK1/2 ph

29 affinity for the GLP-1 receptor and enhanced oxyntomodulin-mediated GLP-1 receptor signaling as measu

30 Oxyntomodulin most potently enhanced glucose uptake in t

31 intravenous infusions of either PYY(3-36) or oxyntomodulin or combined PYY(3-36)/oxyntomodulin.

32 As opposed to singular incretin effects, oxyntomodulin (OXM) activates glucagon receptors (GCGR)

33 Here we show how G49, an oxyntomodulin (OXM) analog and dual glucagon/glucagon-li

34 peptide-1 (GLP-1), cholecystokinin (CCK) and oxyntomodulin (OXM) as treatments for obesity-diabetes.

35 on-like peptide (GLP-1), glucagon (GCG), and oxyntomodulin (OXM) directly into the brain.

36 Oxyntomodulin (OXM) is a glucagon-like peptide 1 (GLP-1)

37 Application of this strategy to oxyntomodulin (OXM), a peptide hormone that stimulates i

38 food-driven liver clock resetting involving oxyntomodulin (OXM).

39 ulating peptide YY, glucagon-like peptide 1, oxyntomodulin, pancreatic polypeptide, leptin, and adipo

40 as cholecystokinin, glucagon-like peptide 1, oxyntomodulin, peptide YY, orexin A and ghrelin.

41 ake during coadministration of PYY(3-36) and oxyntomodulin was reduced by 42.7% in comparison with th

42 erum for at least 5 days as compared to free oxyntomodulin which is undetectable after only 4 h.

43 ing the low-affinity GLP-1 receptor agonist, oxyntomodulin, would improve the insulin secretory prope